DDR1 promoted development in orthotopic glioblastoma mouse models and human ER-positive, HER2-negative breast cancer and reduced the efficacy of chemotherapy agents by activating the AKT signaling pathway in these tumor cells11,12. This evidence concerns the gene AKT1 and glioblastoma.